TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN

Journal of Interferon and Cytokine Research

Volumn 28, Issue 4, 2008, Pages 253-263

  Inglefield, Jon R ^a,b   Dumitru, Calin Dan ^a,c   Alkan, Sefik S ^a,d   Gibson, Sheila J ^a   Lipson, Kenneth E ^a,e   Tomai, Mark A ^a   Larson, Chris J ^a,f   Vasilakos, John P ^a,g  

^a 3M COMPANY   (United States)

^b Meso Scale Discovery   (United States)

^c GENENTECH INC   (United States)

^d Alba Therapeutics Corporation   (United States)

^e FIBROGEN INC   (United States)

^f R and D Systems Inc   (United States)

^g Biothera   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

852A; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ALPHA INTERFERON ANTIBODY; BETA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P70; INTERLEUKIN 18; MONOCYTE CHEMOTACTIC PROTEIN 1; N [4 (4 AMINO 2 ETHYL 1H IMIDAZO[4,5 C]QUINOLIN 1 YL)BUTYL]METHANESULFONAMIDE; OMEGA INTERFERON; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SUPERNATANT;

AMINOQUINOLINES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; HUMANS; INTERFERON TYPE I; LEUKOCYTES, MONONUCLEAR; LUNG; MELANOMA; MICE; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; QUINOLINES; SUBCELLULAR FRACTIONS; SULFONAMIDES; TOLL-LIKE RECEPTOR 7;

EID: 42549128230     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0097     Document Type: Article

References (53)

1. Ahmed I, Berth-Jones J. 2000. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 143:843-845.
2. An H, Zhu J, Wang X, Xu X. 2006. Synthesis and anti-tumor evaluation of new trisulfide derivatives. Bioorg Med Chem Lett 16: 4826-4829.
3. Ashkenazi A, Dixit VM. 1999. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260.
4. Basham TY, Bourgeade MF, Creasey AA, Merigan TC. 1982. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci USA 79:3265-3269.
5. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. 2002. Interferonalpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134.
6. Bingle L, Brown NJ, Lewis CE. 2002. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 196:254-265.
7. Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, Nikolsky Y. 2007. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunol 8:26-45.
8. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. 2002. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205:135-138.
9. Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ. 2006. Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci 47:2959-2965.
10. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens JP, Plumas J. 2006. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176:248-255.
11. Chapman MS, Spencer SK, Brennick JB. 2003. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 139:943-944.
12. Clemens MJ. 2003. Interferons and apoptosis. J Interferon Cytokine Res 23:277-292.
13. Czarniecki CW, Fennie CW, Powers DB, Estell DA. 1984. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol 49:490-496.
14. Dudek AZ, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. 2007. First in human phase I trial of a novel systemic TLR7 agonist to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 13(23):7119-7225.
15. Dunn GP, Old LJ, Schreiber RD. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148.
16. Epstein E. 2003. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 139:944-945.
17. Evinger M, Maeda S, Pestka S.1981. Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem 256:2113-2114.
18. Faith A, Peek E, McDonald J, Urry Z, Richards DF, Tan C, Santis G, Hawrylowicz C. 2007. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am J Respir Cell Mol Biol 36:360-367.
19. Ghosh TK, Mickelson DJ, Solberg JC, Lipson KE, Inglefield JR, Alkan SS. 2007. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type 1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol 7:1111-1121.
20. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP. 2002. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218:74-86.
21. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174:1259-1268.
22. Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS. 2006. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18:1115-1126.
23. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200.
24. Heron I, Hokland M, Berg K. 1978. Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 75:6215-6219.
25. Hoption Cann SA, van Netten JP, van Netten C, Glover DW. 2002. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 58:115-119.
26. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537.
27. Inglefield JR, Larson CJ, Gibson SJ, Lebrec H, Miller RL. 2006. Apoptotic responses in squamous carcinoma and epithelial cells to smallmolecule toll-like receptor agonists evaluated with automated cytometry. J Biomol Screen 11:575-585.
28. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. 2001. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388-3393.
29. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863-869.
30. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556-7561.
31. Kirkwood JM. 2000. Adjuvant interferon in the treatment of melanoma. Br J Cancer 82:1755-1756.
32. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. 2000. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458.
33. Krieg AM. 2002. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760.
34. Lewis C, Murdoch C. 2005. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 167:627-635.
35. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555.
36. Medzhitov R, Janeway C Jr. 2000. The toll receptor family and microbial recognition. Trends Microbiol 8:452-456.
37. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL. 2003. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 149(Suppl 66):66-70.
38. Penn I. 2000. Post-transplant malignancy: the role of immunosuppression. Drug Saf 23:101-113.
39. Pinzon-Charry A, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Lopez JA. 2006. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 8:R5-14.
40. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, French LE. 2006. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 176:61-67.
41. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835-1837.
42. Solly K, Wang X, Xu X, Strulovici B, Zheng W. 2004. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2:363-372.
43. Steinmann A, Funk JO, Schuler G, von den Driesch P. 2000. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43:555-556.
44. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. 2003. The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149(Suppl 66):53-56.
45. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu Rev Immunol 21:335-376.
46. Thomas-Tikhonenko A, Hunter CA. 2003. Infection and cancer: the common vein. Cytokine Growth Factor Rev 14:67-77.
47. Torcia M, Lucibello M, De Chiara G, Labardi D, Nencioni L, Bonini P, Garaci E, Cozzolino F. 1999. Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit. Biochem Biophys Res Commun 262:838-844.
48. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S. 2004. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466-7474.
49. Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Gilliet M. 2005. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97:1143-1153.
50. Vicari AP, Caux C, Trinchieri G. 2002. Tumor escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12:33-42.
51. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. 2003. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 139:273-276.
52. Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, Wang XB, Xu X. 2005. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18:154-161.
53. Yanai Y, Horie S, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M, Kitamura T. 2001. Characterization of the antitumor activities of IFN-α8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res 21:1129-1136.